Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISV-620
- Development stage
- Preclinical
- Lead developer
- Sun Pharma
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
ISV-620 is a small molecule prostaglandin analog developed by InSite Vision (now a subsidiary of Sun Pharma) for cosmetic eyelash enhancement. The product is formulated using the proprietary DuraSite drug delivery technology, a mucoadhesive polymer-based system designed to stabilize the drug and extend its residence time on the ocular surface. By acting as an agonist at prostaglandin receptors, ISV-620 is intended to promote the growth phase of the eyelash hair cycle, resulting in longer, thicker, and darker lashes. The program was reported to be in the IND-enabling stage of development prior to the acquisition of InSite Vision by Sun Pharma.
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on ISV-620.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISV-620.